 Among the eight EMA products with a HRQL claim, five products have been also approved by the FDA. In two cases (apremilast and ustekinumab), the medical review was not available. Therefore, reasons for not including HRQL in the label could not be retrieved. For the three other products (adalimumab, infliximab, secukinumab), HRQL was not mentioned in the review.  In contrast with the FDA, the EMA seems to consider HRQL as a valuable endpoint in the evaluation of psoriasis products.  More harmonization between these agencies might be beneficial in providing useful information to patients with psoriasis.
DOES HEALTH-RELATED QUALITY OF LIFE EVALUATION IN PSORIASIS MATTER? A REVIEW OF LABELS OF PSORIASIS PRODUCTS APPROVED BY THE FDA AND EMA
 Psoriasis is a papulosquamous skin disease characterized by recurring thick, itchy, and dry red patches covered with silvery scales. Several studies have shown that psoriasis has a profound impact on the health-related quality of life of patients. [1] [2] [3]  The objective of this study was to evaluate how health-related quality of life (HRQL) has been taken into consideration in the evaluation of psoriasis products approved by the FDA and the EMA since 1995.
 The websites of the FDA and the EMA were explored to identify all psoriasis products approved. The search was performed on May 7, 2015.
 PROLabels was used to identify products with a PRO claim in label. All corresponding clinical reviews (FDA) and assessments reports (EMA) were reviewed for HRQL evaluation.
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For more information, please contact: Catherine Acquadro, cacquadro@mapigroup.com www.mapigroup.com In Studies ESTEEM 1 and ESTEEM 2, significant improvements in quality of life as measured by the Dermatology Life Quality Index (DLQI) and the SF-36v2MCS were demonstrated in patients receiving apremilast compared with placebo-treated patients (Table 4) . Improvements in DLQI were maintained through Week 52 in subjects who were rerandomized to apremilast at Week 32 ( Table 2 below) and on all the secondary efficacy endpoints. Statistically significant improvements at Week 12 (Studies 1-4) from baseline compared to placebo were demonstrated in the DLQI (Dermatology Life Quality Index). Mean decreases (improvements) in DLQI from baseline ranged from -10.4 to -11.6 with secukinumab 300 mg, from -7.7 to -10.1 with secukinumab 150 mg, versus -1.1 to -1.9 for placebo at Week 12. These improvements were maintained for 52 weeks (Studies 1 and 2).
Methods

Conclusions
Results
REFERENCE NUMBER(S)
EMEA/H/C/000958EMA ustekinumab Stelara 
